β1 integrin signaling has been shown to mediate cellular resistance to apoptosis after exposure to ionizing radiation (IR). Other signaling molecules that increase resistance include Akt, which promotes cell survival downstream of β1 integrin signaling. We showed previously that β1 integrin inhibitory antibodies, AIIB2, enhance apoptosis and decrease growth in human breast cancer cells in 3 dimensional laminin-rich extracellular matrix (3D lrECM) cultures and in vivo.
Introduction
Radiation therapy is an effective modality used for breast cancer treatment, however, tumor resistance and recurrences remain significant clinical problems (1) . Increasing evidence indicates that in addition to DNA damage, multiple cellular mechanisms such as cell interactions with neighboring cells and the microenvironment fundamentally influence cell fate in response to ionizing radiation (IR) (2) . Indeed, single doses of IR to single cells could modify cell-cell and cell-extracellular matrix (ECM) interactions and confer heritable epigenetic traits (3).
Adhesion to ECM has long been known to modify radiation sensitivity in several cell types, including cancer. Integrins, a major class of transmembrane molecules that mediate adhesion and cell-ECM interactions are aberrantly expressed in many cancer cell types, and are upregulated post-IR (4, 5) . In particular, β1 integrins have been found to be upregulated by clinically relevant doses of IR in cancer cell lines (4) and in human mammary epithelial cells in 3 dimensional laminin rich extracellular matrix (3D lrECM) cultures (3, 5) . β1
integrins have been implicated in mediating resistance to IR (6) (7) (8) (9) (10) ; However, the role of β1 integrins as a strategic molecular target in conjunction with IR has not been fully investigated.
β1 integrins belong to a family of heterodimeric receptors whose ligands are arginine-glycine-aspartic acid (RGD) -containing ECM molecules (11) . Acting largely as mechanoreceptors, β1 integrins transmit biochemical cues that can facilitate multiple cellular fates downstream, including apoptosis and survival (12) .
Increase in β1 integrins appear to enhance cancer cell viability by promoting survival, and confer resistance to chemotherapy in several tumor cell types (10, 13, 14) . In addition, we have shown previously that in a subset of patients with early stage breast cancer, high β1 integrin expression is associated with poor overall survival, indicating that this subgroup of patients may benefit from more aggressive and targeted therapy (15) .
Cancer cell resistance to IR has been shown previously to be mediated via Akt, a serine threonine kinase that lies immediately downstream of phoshatidyl-inositol-3 (PI3) kinase and the integrin signaling pathways (16, 17) .
β1 integrin has been shown to enhance cancer cell survival via the PI3 kinase pathway in lung cancer (10) and in normal fibroblasts (18) in culture. We have shown previously that β1 integrin inhibitory antibodies selectively induce apoptosis in breast cancer cells but not non-malignant acini in 3D lrECM cultures; these findings were validated in vivo with no toxicity to animals (19), indicating that β1 integrin is a highly promising therapeutic target. In this report, we used the 3D lrECM assay and in vivo models of breast cancer to test the hypothesis that β1 integrins may facilitate IR-induced resistance by promoting Akt-mediated survival.
Materials and Methods

Cell Culture
Non malignant human mammary epithelial cells, HMT-3522 (S-1), were originally derived from a woman with fibrocystic breast disease (20) , and were cultured in H14 medium (21) . S-1 cells were propagated on plastic in medium containing 10ng/ml EGF. Also derived from the same parental line, malignant HMT-3522 (T4-2) cells were propagated on collagen type I-coated flasks in the absence of EGF (21) . T4-2 wild type cells that were either stably transfected with a constitutively active myristoylated Akt (T4-2 myrAKT) or empty vector control (T4-2 vc) were a gift from Hong Liu, UCSF. Human breast cancer cell line, MCF- Cell lines were maintained in H 14 media as described previously (19) and transferred to the modified 3D lrECM assay (19). This is referred to as Day 0.
Cultures were exposed to ionizing radiation (IR) and/or AIIB2 on Day 6 of culture after acinar formation for non-malignant S1 cells and on days 4 and 5 of culture, sequentially for malignant cell lines. AIIB2 was added to culture medium on alternate days. All cultures were analyzed 72 hours after the first treatment.
AIIB2
β1 integrin function-blocking antibody, clone AIIB2, was originally a purchased gift from Carolyn Damsky at UCSF. AIIB2 is a rat monoclonal IgG 1 that was isolated from a human choriocarcinoma hybridoma that specifically binds β1 integrin extracellular domain (22) (23) (24) . Prior experiments using F(ab') 2 fragments of enzyme-digested AIIB2 indicated that the epitope-binding portion of the antibody was active, and resulted in down-modulation of β1 integrin-mediated signaling (21, 25) .
Apoptosis and Proliferation Assays in 3D lrECM
Proliferating cells from 3D lrECM cultures were detected by indirect immunoflourescence of Ki-67 nuclear antigen. Samples taken from cultures were fixed onto glass slides using methanol/acetone and blocked in 10% goat serum for one hour at room temperature in a humidified chamber. Slides were then incubated in primary rabbit antibody against Ki-67, clone MIB-1, (Novocastra Laboratories, Norwell, MA) for 1 hour. After washing in PBS, FITCconjugated anti-rabbit secondary antibody (Jackson Laboratories, Bar Harbor, ME) was applied for 1 hour in a dark humidified chamber. Slides were then washed and counterstained with DAPI before mounting with Vectashield mounting medium (Vector Laboratories, Burlingame, CA). Apoptosis was assayed by detecting terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) in samples taken from 3D lrECM cell culture using a commercially available kit (In Situ Cell Death Detection Kit, Fluorescein; Roche, Nutley, NJ). Samples from cultures were fixed onto glass slides in 4% paraformaldehyde and permeabilized in 0.1% Triton X-100 in 0.1% sodium citrate. After washing, cells were incubated in TUNEL reaction mixture at 37ºC for 60 minutes and mounted.
Fluorescence Activated Cell Sorting (FACS) Analysis
S-1 and T4-2 cells grown on tissue culture plastic were harvested using 0.25% trypsin. After resuspending cells in DMEM/F-12 media containing trypsin inhibitor, cells were spun down and washed in 5% fetal bovine serum and 0.1% sodium azide in PBS on ice. Cells were incubated first in dilute primary Annexin V antibody (Trevigen, Gaithersberg, MD) for at 4°C for 30-60 minutes, then washed and incubated with a flourescein-conjugated IgG secondary antibody (1:100) for 30-60 minutes. After washing, the pellet was immediately suspended in 1% paraformaldehyde. Cells were analyzed using a Beckman-Coulter EPICS XL-MCL Analyzer. System II Data Acquisition and Display software, version 2.0 was used for data analysis.
Colony forming assays
T4-2 and S-1 cells were propagated on 2D as previously described (21) .
After reaching 50-70% confluence, culture flasks were exposed to IR (Sham, 2, 4 or 8 Gy). Six hours later, they were trypsinized and replated onto 35mm per well dishes and allowed to grow for 10-12 days. Dishes were treated with crystal violet and colonies with greater than 50 cells were counted. Six wells per condition were plated for n=3 experiments. Plating efficiencies and surviving fractions were estimated based on binomial probability distribution.
Western Immunoblot
To release cells from 3D lrECM, cultures were first treated with ice-cold PBS/EDTA (0.01M sodium phosphate [pH 7.2] containing 138 mM sodium chloride and 5mM EDTA) and then lysed in RIPA buffer as previously described (21) . Protein was aliquoted onto reducing SDS gels in equal amounts and separated using low voltage current. Protein bands were transferred onto nitrocellulose membrane (Invitrogen, Carlsbad, CA), and blots were blocked with 5% nonfat milk. Blots were probed with antibodies as listed below, then washed, incubated with secondary antibody and exposed to x-ray film. Antibodies used 
Statistical Analysis
For Ki-67 and TUNEL counts in 3D lrECM, each culture condition, eg) each dose of AIIB2 or IgG and each dose of IR in both sequences) was compared in pair-wise fashion and Chi-square statistics were calculated for significant differences between groups. A p-value of <0.05 was considered to be an association that had a 95% probability of not being due to chance alone.
We estimated the numbers of animals needed for each experiment based on our prior experience with the MCF-7 xenograft models (19). 
3D lrECM
The original 3D assay developed by Petersen and Bissell laboratories (26) consisted of breast cells suspended in a laminin-rich extracellular matrix. Under these conditions, non-malignant and malignant cells can be rapidly and robustly distinguished from each other (26) . We modified this assay to use as a screen for novel therapies and showed that it could be used as a surrogate to discriminate between normal and malignant tissue response to β1 integrin inhibitory antibody in vivo (Park et al 2006) .
In the present study, we used the modified 3D lrECM assay to compare apoptotic response of malignant colonies and non-malignant acini to IR with and without β1 integrin inhibitory antibody. We treated the preformed S1 and T4-2 structures with 8 Gy IR or 0.08 mg/ml β1 integrin inhibitory antibody (AIIB2) alone or in combination where AIIB2 was added to the culture medium for 24 hours and To determine whether these findings were generalizable to other breast cancer cell lines, we used MCF-7 cells, a widely used model for breast cancer. In addition, to determining the optimal sequence of therapy, we treated 3D lrECM cultures with AIIB2 both before and after exposure to IR (Figure 2A ). Compared to colonies that were treated with IR and a non-specific antibody control, colonies treated with combined IR and AIIB2 in either sequence showed an appreciable decrease in total cell numbers (data not shown) and a significant increase in apoptosis (assayed by TUNEL) compared to IR alone ( Figure 2B ). The observed differences with untreated control were larger when IR was given before AIIB2; however, the data did not reach statistical significance to a level of 95% certainty we assayed 3D lrECM cultures for levels of p-S473 Akt after exposure either to IR and control IgG antibodies or a combination of IR and AIIB2 with the latter applied both before and after IR. We found that down regulation of Akt activity occurred when AIIB2 was administered post-IR, Figure 2C . Interestingly, Akt activity after 6 hours of AIIB2 treatment alone did not decline once the cancer cells had already formed colonies ( Figure 2C ). We further verified these results in T4-2 cells in 3D lrECM (Supplemental Figure 2C ) and found no significant change in Akt activity after similar treatment of non-malignant S-1 structures (Supplemental Figure 2D) .
IR-induced Akt effects could be overcome by application of β1 integrin inhibitory antibody
In order to evaluate whether apoptosis induced by β1 integrin inhibition or IR operated directly through Akt signaling, we utilized T4-2 cells transfected with a constitutively activated, myristoylated form of Akt (myr-Akt) (30, 31) , (the construct was a kind gift of R. Roth,(32)) Figure 3A . We measured apoptosis using TUNEL in T4-2 myrAkt colonies after either IR alone or in combination with 0.08 mg/ml AIIB2 -the dose used previously to induce apoptosis in several breast cancer cell lines in 3D lrECM (19). In contrast to T4-2 vector controls, which showed increased apoptosis after IR plus 0.08 mg/ml AIIB2, T4-2 myrAkt colonies were refractory to this treatment ( Figure 3B ).
We reasoned that if Akt activity was responsive to β1 integrin signaling, Figure 3D ). Moreover, treatment with these higher doses of AIIB2 corresponded to downregulation in p-S473 Akt and p-Thr1462 TSC-2.
Taken together, these data strongly suggest that IR resistance is in part mediated by activation of β1 integrin and a subsequent increase in Akt signaling both of which could be abrogated by β1 integrin inhibition.
Combining β1 integrin inhibition with IR treatment in vivo allows reduction of the effective dose of IR
Given the promising results in 3D lrECM, we asked whether these data could be validated in vivo. Following implantation of MCF-7 cells into the rear flank of female athymic nu-/-mice (n=14 per group), animals were subsequently randomized to receive either IR and control IgG, IR followed by AIIB2 or AIIB2
followed by IR, as described in Material and Methods ( Figure 4A ). Overall, the addition of AIIB2 to IR enhanced tumor growth inhibition compared to either treatment alone (Supplemental Figure 3) . Remarkably, we found that animals that received 2 Gy followed by AIIB2, had similar tumor growth inhibition to those that received 8 Gy with control antibody (p<0.014; Figure 4B ). We measured apoptosis at 24 hours after the final treatment in each group and found that tumors treated with 2 Gy plus AIIB2 also had a higher rate of apoptosis compared to other groups ( Figure 4B ).
To verify whether Akt activity was downregulated by combined treatment as we had observed in 3D lrECM, we assayed whole tumor cell lysates for evidence of Akt activity by probing for phosphorylation of S473 Akt. Again, the in vivo results replicated the findings in 3D: we observed an increase in AKT activity associated with IR dose, which was down modulated by the addition of AIIB2
after IR ( Figure 4C ).
Discussion
Here we report promising results combining β1 integrin inhibitory antibody with IR to decrease the total effective radiation dose and to maximize the efficacy of treatment by sensitizing the tumor, but not normal organs, to IR. Our increasing awareness of the global effects of IR on tissues, and the role of the microenvironment on modifying cellular response to IR (2, 33) Although there was a trend that favored sequencing IR followed by AIIB2, this did not achieve a statistical significance between the two treatment regimes over multiple repeated experiments. One of the likely reasons for this finding is that the magnitude of effect of AIIB2 alone was greater than a measurable difference attributed solely to the sequence of treatment. Importantly, AIIB2 was maintained continuously in the 3D lrECM cultures as it would be also in vivo.
Studies that examined the effect of sequencing PI3 kinase inhibitor, LY294002, in breast cancer cells in 2D culture (36) reported an optimal increase in apoptosis after combined IR and LY when LY was given both pre-and post-IR. However the effects of the inhibitor and IR in non-malignant cells was not reported.
Another group (37) Our data complement those of others who showed that survival of bladder cancer cells harboring a mutation in ras was significantly decreased after combined treatment with LY294002 and IR, although these investigators reported no significant benefit of LY alone either in 2D cultures or in vivo (16, 39) . Others also have reported a synergistic effect of LY294002 and IR for glioblastoma multiforme xenografts (27) . Although dose-limiting toxicity and pharmacokinetics limit LY294002 as a viable drug in humans, these studies highlight the importance of targeting Akt in conjunction with IR. In addition, Akt has been shown to be a promising target in cancer cells downstream of integrins and growth factor pathways post IR (17) . Thus, multiple pathways at the cell surface converge at Akt via PI3 kinase, a central mediator of cancer cell survival, which may be targeted simultaneously to enhance therapeutic efficacy. Our data point to the existence of an IR-dependent survival pathway mediated by Akt that is down modulated with β1 integrin inhibition. It is quite possible that IR affects polarity pathways involving Rac 1 (32) , which was shown also to affect radiationinduced apoptosis (40, 41) .
We found that the addition of AIIB2 treatment to IR in vivo resulted in significant improvement in inhibition of tumor growth by allowing a much smaller dose of IR (2 Gy) but reaching the same end point of higher doses of IR alone (8 Gy). To our knowledge, this is the first report of a β1 integrin inhibitor used in conjunction with IR in a therapeutic context in vivo.
There was a modest improvement in tumor growth inhibition associated with the addition of AIIB2 to 8
Gy compared to 8 Gy alone. But improvement on 2GY of radiation was considerable. These data suggest that there may be an IR dose threshold above which the addition of AIIB2 has decreasing value in enhancing tumor cell death.
We acknowledge that the doses and single fractions used in these experiments may not be the optimal dosing and sequencing in humans, however these data provide proof of principle that the combination of β1 integrin inhibition and IR are a promising novel strategy for breast cancer radiotherapy. 
